Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
|Videos|January 27, 2022
Robert S. Kirsner, MD, PhD,’s Wound Healing Pearls
Author(s)Katie Hobbins
Robert S. Kirsner, MD, PhD, discusses new and tried-and-true wound healing methods in his presentation at the Maui Derm for Dermatologists meeting.
Advertisement
Robert S. Kirsner, MD, PhD, chairman and Harvey Blank professor in the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine in Miami, Florida, shares his pearls for greater efficacy in his presentation at the current Maui Derm for Dermatologists meeting held in Maui, Hawaii. His pearls included: letting evidence guide decisions, debriding the wound edge along with the wound, using microbes to improve healing, and more.
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5